

DABIGATRAN ETEXILATE (PRADAXA®)

Trademark Pradaxa®
(in Japan: Prazaxa®)

EXECUTIVE SUMMARY

- Dabigatran etexilate (Pradaxa®) is a non-vitamin K antagonist oral anticoagulant targeting a high unmet medical need in thromboembolic diseases
- Dabigatran was the first novel breakthrough anticoagulation therapy in over 50 years approved for the prevention of stroke and systemic embolism for adult patients with non-valvular atrial fibrillation (AF) and one or more risk factors for stroke*¹
- In 2014, dabigatran was approved by the European Commission and the US Food and Drug Administration (FDA) for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).^{1,2} Since 2008, dabigatran has also been approved for the primary prevention of blood clots (venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery)¹
- Clinical experience of dabigatran in all licensed indications is already well established and continues to grow, equating to over 4.6 million patient-years in more than 100 countries worldwide³
- Dabigatran is the only non-vitamin K antagonist oral anticoagulant with more than six years' experience in stroke prevention in AF and long-term data demonstrating the sustained efficacy and safety profile of the treatment in the clinical setting^{4,5}
- The efficacy and safety profile of dabigatran has been intensely studied during the RE-VOLUTION® clinical trial programme,^{4,6-12} as well as evaluated by Regulatory Authorities in real world clinical practice¹³⁻¹⁵

*Prior stroke or transient ischaemic attack; age ≥75 years; heart failure (New York Heart Association [NYHA] Class ≥II); diabetes mellitus; hypertension.¹

Profile


Dabigatran is a novel reversible oral direct thrombin inhibitor that specifically and selectively blocks the activity of thrombin (both free and clot bound), the central enzyme in clot (thrombus) formation.^{16,17}

Dabigatran has a number of characteristics which distinguish it from the long-time standard of care vitamin K antagonist (VKA) therapy (e.g. warfarin):

- Does not require routine coagulation monitoring or dose titration¹⁷
- Predictable and reproducible anticoagulant effect¹⁷
- Rapid onset/offset of action¹⁷
- Low potential for drug–drug interactions¹⁷
- No food–drug interactions and dosing independent of meals or dietary restrictions¹⁸



Does not require routine coagulation monitoring or dose titration



Low potential for drug-drug interactions



No food-drug interactions and dosing independent of meals or dietary restrictions

Mode of action

Unlike other anticoagulants, the effects of direct thrombin inhibitors such as dabigatran are targeted specifically to thrombin.¹⁷

Thrombin is an enzyme in the blood that causes blood to clot by facilitating the conversion of the protein fibrinogen to fibrin. Thrombin clips a small piece off the large protein fibrinogen, converting fibrinogen from a soluble substance into insoluble fibrin, causing it to assemble into large fibrous networks. These networks of fibrin strands then trap blood cells, leading to the formation of blood clots or thrombi, which may ultimately lead to venous thromboembolism and stroke.¹⁶

Dabigatran works by specifically and selectively binding to both free and clot-bound thrombin, blocking its activity and effect on blood clotting.¹⁷

Indications & approvals

In 2008, the European Commission granted EU approval for dabigatran for the primary prevention of venous thromboembolic events (blood clots) in adults who have undergone elective total hip or total knee replacement surgery. Following this, in October 2010 dabigatran was approved in the US for the prevention of stroke and systemic embolism in adult patients with non-valvular AF with one or more risk factors,^{*2} It was then subsequently approved in the EU in August 2011 for this indication.¹

In June 2014, dabigatran was approved by the European Commission for the treatment and prevention of recurrence of DVT and PE.¹ The U.S. Food and Drug Administration (FDA) approved dabigatran earlier in

Dabigatran etexilate (Pradaxa®)

2014² and approvals have now been achieved in over 70 countries worldwide. Further registration processes are ongoing in other markets.³

The benefits from dabigatran have been widely recognised, leading to regulatory approvals in over 100 countries worldwide. Clinical experience of dabigatran is already well established and continues to grow, equating to over 4.6 million patient-years globally in all licensed indications.³

Key therapeutic areas under ongoing investigation

The effectiveness and favourable safety profile of dabigatran has been proven within an extensive clinical trial programme, passing independent regulatory approvals worldwide. Boehringer Ingelheim is undertaking ongoing investigation into key areas of unmet need with dabigatran. The extensive RE-VOLUTION® clinical trial programme is evaluating the efficacy and safety of dabigatran against current standard therapies in major therapeutic areas. Upon completion, the clinical trial programme will involve over 60,000 patients in more than 100 countries globally.^{3,4,6–12,19–23}

RE-VOLUTION® Phase III trials	Indication under investigation
RE-NOVATE® ⁸ & RE-NOVATE® II ⁹	Primary prevention of VTE following hip replacement surgery
RE-MODEL™ ¹⁰	Primary prevention of VTE following knee replacement surgery
RE-MOBILIZE® ²⁰	Primary prevention of VTE following knee replacement surgery
RE-LY® ^{6,7} /RELY-ABLE® ^{4,5}	Prevention of stroke in patients with non-valvular AF at risk of stroke
RE-COVER® ¹¹ & RECOVER® II ¹¹	Treatment of acute VTE
RE-MEDY™ ¹²	Secondary prevention of VTE
RE-SONATE® ¹²	Secondary prevention of VTE

Boehringer Ingelheim has announced plans to initiate further large, global clinical trials and registries of dabigatran to evaluate its potential for reducing risk of stroke and other life-threatening events in areas of particular unmet medical need:^{3,21–23}

- RE-SPECT ESUS™⁺ will investigate the efficacy and safety of dabigatran in patients whose first stroke was embolic of undetermined source (ESUS). Embolic strokes occur when a blood clot forms somewhere in the body and travels through the bloodstream to the brain
- RE-DUAL PCI™ will evaluate the efficacy and safety of dabigatran in patients with non-valvular atrial fibrillation who have undergone percutaneous coronary intervention (PCI), also known as angioplasty, with stenting
- RE-CIRCUIT™ will investigate the efficacy and safety of uninterrupted anticoagulant treatment with dabigatran in patients with atrial fibrillation who undergo ablation. Ablation is a routine, minimally invasive procedure that is conducted to normalise the heart rhythm

*Dabigatran is not approved in any country for patients with ESUS. The new trial announcements contained within this factsheet have not received indication approvals.

Dabigatran etexilate (Pradaxa®)

- RE-COVERY DVT/PE™ will provide real-world data on the use of anticoagulants in acute DVT and PE treatment in real-world clinical practice. The registry will generate further evidence on the effectiveness and safety of the two approved doses of dabigatran compared to the vitamin K antagonist warfarin.

The studies began enrolment in 2014 and 2015, and will form part of the extensive RE-VOLUTION® clinical trial programme.

The Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA™-AF) will collect important data on the safety and comparative effectiveness of anticoagulant treatments, including warfarin, acetylsalicylic acid (ASA) and non-vitamin K antagonist oral anticoagulants, such as dabigatran. Up to 56,000 patients are planned for enrolment across 2,200 sites in 50 countries by 2020, with data being collected from general practices, specialist offices, community hospitals, university hospitals, outpatient care centres and anticoagulation clinics.²⁴

Stroke prevention in non-valvular atrial fibrillation


RE-LY® (Randomized Evaluation of Long-term anticoagulant therapy) was a global, Phase III, PROBE (prospective, randomized, open-label with blinded endpoint evaluation) trial of 18,113 patients enrolled in over 951 centres in 44 countries. It was designed to compare two fixed doses of the oral direct thrombin inhibitor dabigatran (110 mg and 150 mg twice daily) each administered in a blinded manner, with open label warfarin (INR 2.0–3.0, median TTR 67%¹).^{6,7,25}

Key fact: RE-LY® was one of the largest Phase III trials for stroke prevention in AF, enrolling 18,113 patients in 951 centres in 44 countries. RE-LY® investigated two doses of dabigatran in a randomised fashion against well-controlled warfarin.⁶

The RE-LY® trial showed that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in AF^{6,7} in an intention-to-treat (ITT) analysis (the ITT analysis represents the highest standard for analysing superiority in non-inferiority trials).^{6,7}

Results from RE-LY® demonstrated:^{6,7}

- Dabigatran 150 mg twice daily reduced the risk of stroke and systemic embolism by 35% compared to warfarin




- Dabigatran 110 mg twice daily showed a similar reduction in the risk of stroke and systemic embolism compared to warfarin.^{6,7} Dabigatran 110 mg twice daily is indicated for certain patients with AF including those aged over 80 years, and those with medical conditions such as decreased renal function or taking concomitant treatments, which put them at higher risk of bleeding.¹

Dabigatran 150 mg twice daily is the only non-vitamin K antagonist oral anticoagulant, study of which has shown a significant reduction of both ischaemic and haemorrhagic strokes compared to warfarin in the pivotal RE-LY® trial.^{6,7}

In terms of reductions in rates of life-threatening bleeding events and intracranial bleeding, treatment with dabigatran was associated with considerable benefit.^{6,7}

- Dabigatran 110 mg twice daily showed lower rates of major bleeding compared to warfarin – the primary safety endpoint of the RE-LY® trial
- Both the 150 mg and 110 mg dose of dabigatran showed lower rates of life-threatening and intracranial bleeding than warfarin
- Dabigatran 150 mg twice daily had similar rates of major bleeding as warfarin – the primary safety endpoint of the RE-LY® trial
- Dabigatran 150 mg twice daily showed a significant reduction in rates of vascular mortality compared to warfarin.



Following in-depth evaluations of the safety and efficacy of dabigatran, Regulatory Authorities including the European Medicines Agency (EMA) and FDA have reconfirmed the favourable benefit–risk profile of the anticoagulant treatment. The agencies' findings support the substantial benefits that dabigatran offers in real-world clinical practice to patients worldwide.^{13–15}

Long-term protection: RELY-ABLE®

Dabigatran is the first and only non-vitamin K antagonist oral anticoagulant with controlled long-term clinical trial data extending beyond 6 years of ongoing treatment. Results from the RE-LY® follow-up study RELY-ABLE® demonstrate the sustained protection offered by the drug in the clinical setting with good overall long-term safety and tolerability.^{4,5}

To ascertain the long-term effects of dabigatran in stroke prevention and demonstrate the relative benefits of the two doses available, the RELY-ABLE® (Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation) study was undertaken. After completion of the 2 year RE-LY® trial, patients taking dabigatran were followed for a further 2.3 to 4.7 years. The findings demonstrate the long-term protective effects of dabigatran in the clinical setting, with benefits sustained beyond 6 years of ongoing treatment with good overall long-term safety and tolerability.^{4,5}

The unique results from RELY-ABLE® support the benefits of dabigatran beyond six years of long-term treatment:^{4,5}

- During the additional follow-up period which extended to 4.7 years of treatment beyond RE-LY®, rates of major events for both dabigatran 110 mg and 150 mg twice daily were consistent with those seen in RE-LY®.^{4,5}
 - Consistent rates of ischaemic and haemorrhagic stroke, and major bleeding with both doses of dabigatran compared to the event rates that occurred during the RE-LY® trial^{4,5}

Dabigatran etexilate (Pradaxa®)

- The incidence of haemorrhagic stroke was very low and similar between treatment arms^{4,5}
- Very low rates of intracranial bleeding were sustained through the RELY-ABLE® study^{4,5}
- There were no new safety findings identified during the additional observation period of RELY-ABLE®^{4,5}

Prevention of venous thromboembolism (VTE) in patients following total knee or hip replacement

Results from the RE-NOVATE®, RE-NOVATE II® and RE-MODEL™ trials show that dabigatran is as effective as the low-molecular weight heparin, enoxaparin, in preventing VTE after total knee or hip replacement surgery. The safety profile of dabigatran is comparable to enoxaparin after total knee or hip replacement surgery, with a low incidence of major bleeding events^{8–10,20} and no significant difference was observed in the risk of acute coronary syndrome between treatments.²⁶

This evidence from clinical trials is confirmed by experience in the real-world setting. An international observational study with dabigatran 220 mg once daily demonstrated that the treatment offered a good safety profile and was associated with a very low overall incidence of bleeding events, including major bleeding events and major extra-surgical bleeding events. With regards to efficacy, the study showed low incidence of VTE and all-cause mortality.²⁷ These real-world results confirm the benefits of dabigatran for the prevention of VTE in patients undergoing total knee or total hip replacement as previously demonstrated in clinical trials.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrence of DVT and PE

The regulatory approvals of dabigatran in DVT and PE are based on the results of three global Phase III studies (RE-COVER® / RE-COVER® II / RE-MEDY™) involving almost 10,000 patients. Dabigatran was demonstrated to be as effective as warfarin with significantly lower rates of bleeding.^{11,12} Data from a fourth trial (RE-SONATE®) showed a 92% reduction in the risk of recurrent blood clots versus placebo.¹²

Dabigatran is a simple and convenient treatment option for DVT and PE patients and their physicians as it does not require routine dose monitoring, nor a mandatory dose change during the course of treatment. DVT and PE patients can start taking dabigatran in a simple fixed-dose regimen after initial treatment with an injectable anticoagulant such as low-molecular weight heparin.¹

Real world clinical practice

The safety profile of dabigatran has been intensely studied during the clinical trials programme as well as evaluated by Regulatory Authorities in real world clinical practice^{4,6–15}. Both the EMA and FDA have reaffirmed the important health benefits and safety profile of dabigatran for patients with non-valvular atrial fibrillation when used as directed.^{13–15}

The most recent FDA Drug Safety Communication published on 13 May 2014 included results from a Medicare study of more than 134,000 non-valvular atrial fibrillation patients who were 65 years of age or older and new users of either dabigatran or warfarin.^{14,15}

The real-world findings from the Medicare study are consistent with the RE-LY® clinical trial results that provided the basis for the approval of dabigatran^{14,15}. The Medicare study demonstrated that in new users, dabigatran was associated with a lower risk of clot-related strokes, bleeding in the brain and death, than warfarin.^{14,15} In line with the known results of the RE-LY® trial, the Medicare study found an increased risk of major gastrointestinal bleeding in new users of dabigatran compared to warfarin.^{14,15} The myocardial infarction risk was similar for the two drugs.^{14,15}

In the United States, the licensed doses for dabigatran are 150 mg twice daily and 75 mg twice daily for the prevention of stroke and systemic embolism in adult patients with non-valvular AF². The dose of 75 mg twice daily is not authorised in Europe for this indication.⁹

References

1. Pradaxa® European Summary of Product Characteristics, 2015.
2. Pradaxa® US Prescribing Information, 2015.
3. Boehringer Ingelheim data on file.
4. Connolly SJ, *et al.* The long term multi-center extension of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. *Circulation* 2013;**128**:237–43.
5. Ezekowitz MD, *et al.* RE-LY and RELY-ABLE long-term follow-up of patients with non-valvular atrial fibrillation receiving dabigatran etexilate for up to 6.7 Years. Oral Presentation #10684 on Monday 18 November 2013 at the American Heart Association Scientific Sessions, Dallas, Texas, USA.
6. Connolly SJ, *et al.* Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;**361**:1139–51.
7. Connolly SJ, *et al.* Newly identified events in the RE-LY trial. *N Engl J Med* 2010;**363**:1875–6.
8. Eriksson BI, *et al.* Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet*. 2007;**370**:949–56.
9. Eriksson BI, *et al.* Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. *Thromb Haemost* 2011;**105**:721–9.
10. Eriksson BI, *et al.* Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *Thromb Haemost* 2007;**5**:2178–85.
11. Schulman S, *et al.* Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. *Circulation*. 2014;**129**:764–772.
12. Schulman S, *et al.* Extended use of dabigatran, warfarin or placebo in venous thromboembolism. *N Engl J Med* 2013;**368**:709–18.
13. European Medicines Agency Press Release, 25 May 2012: EMA/337406/2012. European Medicines Agency updates patient and prescriber information for Pradaxa. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/news_detail_001518.jsp&mid=WC0b01ac058004d5c1. Last accessed: November 2015.
14. Graham DJ, *et al.* Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation* 2015;**131**:157–64.
15. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin, 13 May 2014. Available at: <http://www.fda.gov/drugs/drugsafety/ucm396470.htm>. Last accessed: November 2015.
16. Di Nisio M, *et al.* Direct thrombin inhibitors. *N Engl J Med* 2005;**353**:1028–40.
17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. *Clin Pharmacokinet* 2008;**47**:285–95.
18. Stangier J, *et al.* Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. *J Clin Pharmacol* 2005;**45**:555–63.
19. Oldgren J, *et al.* Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J* 2011;**32**:2781–9.
20. Ginsberg JS, *et al.* Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *J Arthroplasty* 2009;**24**:1–9.
21. Diener H-C, *et al.* Rationale, objectives and design of a secondary stroke prevention study of dabigatran etexilate versus acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT-ESUS). Presented on 7 May 2014 at the European Stroke Conference, Nice, France.
22. ClinicalTrials.gov. Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting. Available at: <http://clinicaltrials.gov/ct2/show/NCT02164864?term=dabigatran+etexilate&recr=Open&rank=6>. Last accessed: November 2015.
23. Boehringer Ingelheim Press Release. New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation. Available at: http://www.newshome.com/dir/news_releases/press_releases/2014/20_june_2014_dabigatranetexilate.html. Last accessed: November 2015.
24. GLORIA-AF Registry website. Available at: <https://www.gloria-af.com/public/about-objectives.html>. Last accessed: November 2015.
25. Ezekowitz MD, *et al.* Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. *Am Heart J* 2009;**157**:805–10.
26. Eriksson BI, *et al.* Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopaedic surgery: findings from four phase 3 trials. *Thromb Res* 2012;**130**:396–402.
27. Rosencher N, *et al.* Safety and efficacy of once daily 220 mg dabigatran etexilate in a real-world noninterventional study of more than 5000 patients after total knee or hip replacement. Poster Presentation 10001. Presented on 5 November 2012 at the American Heart Association Scientific Sessions.